Following a story · 2 updates
DEA schedules oveporexton in Schedule IV
Aug 6, 2026 – Nov 13, 2026
-
FDA approves first drug treating narcolepsy type 1 at its root cause
The FDA approved Takeda's Orzeyful (oveporexton) on August 5, 2026 as an oral orexin receptor 2 agonist that restores signaling lost in narcolepsy type 1, though the DEA's controlled substance scheduling decision, expected within 90 days, must come before patients can access it through specialty pharmacy.
Read this issue → -
DEA schedules oveporexton in Schedule IV
DEA issued an interim final rule placing Takeda's narcolepsy drug oveporexton (Orzeyful) in Schedule IV, effective November 12, with comments and hearing requests due December 14.
Read this issue →